Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LMFAO literally - doesn't change the facts. I called a 10 bagger and it hit. WHOOPSY = LOL LOL
Gee good thing I called the 10 bagger at .06 - as in 60 cents - and upwards. WHOOPSY!!! = LOL LOL
Like I said previously, I heard the same BS at .06 cents and then it ran to .12 and then to .97. Next
$SXCP looking to set up nicely on the upcoming 10Q!
$212.86 Million in Sales Expected for SunCoke Energy Partners, L.P. (SXCP) This Quarter https://www.americanbankingnews.com/2017/10/19/212-86-million-in-sales-expected-for-suncoke-energy-partners-l-p-sxcp-this-quarter.html
Wall Street analysts expect that SunCoke Energy Partners, L.P. (NYSE:SXCP) will report sales of $212.86 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for SunCoke Energy Partners, L.P.’s earnings, with the highest sales estimate coming in at $231.90 million and the lowest estimate coming in at $193.82 million. SunCoke Energy Partners, L.P. reported sales of $185.50 million in the same quarter last year, which suggests a positive year over year growth rate of 14.7%. The business is scheduled to report its next quarterly earnings results before the market opens on Thursday, October 26th.
Here it is boys and girls! $$$$$$$
http://www.nglenergypartners.com/investor-relations/news/
NGL Energy Partners LP (NYSE:NGL) (the "Partnership" or "NGL") announced today that the Board of Directors of its general partner declared a quarterly distribution of $0.39 per unit, or $1.56 per unit
on an annualized basis, for the quarter ended September 30, 2017. This cash distribution is payable on November 14, 2017 to common unit holders of record at the close of business on November 6, 2017.
Additionally, the Board of Directors declared a distribution for the quarter ended September 30, 2017 to be paid to the holders of the Class A Preferred Units according to the terms outlined in NGL's Partnership Agreement. The Class A Preferred distribution will also be paid on November 14, 2017.
Gee and the facts say otherwise.
I heard the same BS at .06 cents.
Gee 4 Andas at the FDA and another one filed this quarter says otherwise. LOL LOL
Elite shareholders are actually interested in facts as opposed to BS.
Here are the FACTS:
10 FACTS of LIGHT leading to DOLLARLAND = $$$$$$$$$
1) It's important to keep in mind, and as Nasrat will discuss, our resources are being increasingly focused on our generic and opioid pipeline, and preparing for the launch of the generic products already filed with the FDA, as well as the generics which are licensed currently to Epic that will be coming back to Elite in late 2018, when that license expires.
our business is moving away from this type of revenue stream that is dependent on third parties.
2) the resources which were previously utilized for contract manufacturing were allocated to product development. Instead of making Methadone batches, these resources were used to run batches in products which are under development. In addition, we extended our lab and regulatory personnel to support this greatly increased product development activities.
The level of product development activity is the highest that I've seen since I've been here. And I've been with Elite since 2009.
3) there are three ANDAs already filed and under active review with the FDA. Also several other products in various stages of development that we expect will result in more ANDA filings over the near and mid-terms.
4) SequestOx - We are right now focusing on evaluating the right path forward for us to resolve this issue. Epic is negotiating and engaged with us. We've received several phone calls from them, offering their help and we made the announcement regarding the fat study.
5) Our ER products and pipeline are moving forward - And we are pursuing ER formulations. As a matter of fact, most of the money is in the ER extended release formulation
6) We started our aggressive program of filing one ANDA per quarter in Q3 of 2016. We filed one then and we filed another one in Q4, and a third in Q1 of 2017. We missed Q2 of 2017. We are scheduled to file one in Q3 of this year, so it's going to happen way before the end of this quarter and we are scheduled to file another one in Q4 by December.
7) The FDA has granted us 12-month extension for resubmission. One of my main concerns was if we missed this date by December of this year, which we will - that we will end our PDUFA fee and then we'll have to pay another one. We communicated with the FDA and they give us a 12-month extension. Now we can file any time in 2018 up to and through December 31, 2018 without asking for another extension if needed. And if the results are valid, we can proceed within that timeframe without paying another PDUFA fee.
8) we have many other valuable products that are progressing rapidly right now. At Elite, when we were manufacturing a little more, the number of [entries that I remember on our study] [ph] was about 13. And now, we're up to 50 and growing. And the reason we're growing even though the manufacturing part is not our primary focus and small, is because of all of these projects that are going to lead us within the next couple of years to becoming a seriously viable company. FYI, the total market size of the pipeline products that we are co-developing with SunGen is $6 billion.
9) All Elite needs is about $50 million in profit for our stock to go to dollar land, do the math. For our future growth, Elite pipeline will be the driver. We want to ensure a high rate of revenue growth by aggressively targeting one ANDA filing each quarter. Okay. As I stated earlier, out of the last four quarters we have submitted three ANDAs. We are scheduled to submit one this quarter and one in the quarter after.
10) we have completed the expansion of our manufacturing facility in preparation for our new product approval and launches.
Seeing that list never gets old Nasdaq! - And ELTP only needs one!!! $$$$$$$$
Quite a few of the questions as you'd expect were on SequestOx. How close or far off was the actual reformulation and the recent study, the reformulation for SequestOx? The reformulation was an improvement, but not sufficient we believe to satisfy the FDA. Okay.
Is it possible to fix, at what cost and time? We are evaluating our options right now. We are doing a lot of lab work, working with two consultants. And we hope that we will identify a solution and a path forward soon.
Will Elite pursue a resubmission? We need to successful Fed BE first and then we will proceed with that. Is PuraCap Epic still the licensee? Are they still in negotiation? Yes, Epic is still the licensee. We are right now focusing on evaluating the right path forward for us to resolve this issue. Epic is negotiating and engaged with us. We've received several phone calls from them, offering their help and we made the announcement regarding the fat study.
Should Elite drop IR, instant release, and just do an ER product? An interesting question, because the next question says, should Elite drop all other products and focus only on the IR. So I'll try and answer both. First, regarding dropping the IR and just focusing on the ER, I don't find that to be necessary. When we assess the Tmax, we know that it does not apply to the ER products. And our ER products and pipeline are moving forward.
The FDA has granted us 12-month extension for resubmission. One of my main concerns was if we missed this date by December of this year, which we will - that we will end our PDUFA fee and then we'll have to pay another one. We communicated with the FDA and they give us a 12-month extension. Now we can file any time in 2018 up to and through December 31, 2018 without asking for another extension if needed. And if the results are valid, we can proceed within that timeframe without paying another PDUFA fee.
The expected path forward for SequestOx is, first, we are reviewing the alternatives to figure out, what is the best way to resolve the issue with the fat study. Obviously, the easiest way with that have been labeling, take this product have an hour before a meal or two hours after a meal. The FDA did not want that, so we are trying to resolve the issue scientifically and that's taken a little bit of time.
So we are looking at several options, and we will continue to work on that until we resolve this issue. Then we will evaluate the most promising alternative, but this time, we're going to start by doing expensive testing in vitro. It's a lot cheaper and give us a lot better idea on more options. And then we will evaluate the best results and conduct a pilot study.
Then we'll be ready for pivotal study. We will continue working on SequestOx and update you, when a pivotal fatty meal study takes place.
Gee and since Nasrat started at .068 and I called my 10 bagger prior to his coming on board......Yeah there was a 10 bagger........and I called it. Next
Gee you mean R&D companies including Blue Chip companies sells shares for operations - I never heard of this. LMAO!!!
Gee and I'm glad I took advantage and bought hand over fist in the .06's when I called for a 10 bagger.
Sure k - just like the .02's "SOON" won't be here in another 20 plus years and counting. Next
Gee so Nasrat became CEO at .068 and the PPS is .09. Imagine that a penny stock holding a PPS gain for over 4 years.
ELTP is a gem on the OTC.
I heard the same BS at .06 cents when Nasrat became CEO. Remind me again is .09 cents above .068.
Elite has 4 Andas in with the FDA, another filing due this quarter and a partnership with SunGen for another 8 drugs in development. That's the truth. Everything else is spin.
Gee I called a 10 plus bagger at .06 cents and no amount of BS is going to change that fact.
WOW!!!! - did you know the PPS closed GREEN yesterday. Notice the lack of question mark.
It's a warning letter not a company being sued for advertising fraud.........however, this is a penny stock not a blue chip stock giving a 3% dividend. Plan accordingly.
Now I find analysts reports on stocks rather amusing. 11 analysts with an average "HOLD" rating with an average price per share target of $17.17. This stock is a bargain at current prices IMO. However, having said this, I'm hoping the $10.35 50 DMA holds before pushing back over $12 again. I'll have to dig through my couch cushions to find some spare change should that happen.
https://www.americanbankingnews.com/2017/10/18/ngl-energy-partners-lp-ngl-receives-average-recommendation-of-hold-from-analysts.html
Recent Highlights:
1) The CEO recently purchased $665k worth of shares and NGL authorized a $15 million share repurchase program.
2) The Dividend is currently over 14% ..... I get paid a fat dividend to wait for that analyst $17.17.
Now I realize management has missed guidance in some recent quarters but management has shown confidence in their own ability to meet guidance moving forward by #1 above and making changes via changing their operating approach, recontracting and management being willing to evaluate potential asset sales to reduce debt. Seems to me a worthy wait .
I wasn't speaking about the company. Lol
Gee I guess that must be why Nasrat has decided to start filing Andas worth way more than the existing bread crumbs.
Gee and when Elite removes the warning letter and the PPS begins to move up again......I'lll hear some further BS.
Lmao!!! What evidence did I have when I called a 10 plus bagger at .06 cents. Next
Must be why the PPS closed GREEN yesterday - WHOOPSY!!!
Nah the scam is trying to get people to believe Elite isn't going to have another run - that another 10 bagger isn't coming from the existing PPS as I said it would do previously when the stock was at .06 cents.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135516315
10 FACTS of LIGHT leading to DOLLARLAND = $$$$$$$$$
1) It's important to keep in mind, and as Nasrat will discuss, our resources are being increasingly focused on our generic and opioid pipeline, and preparing for the launch of the generic products already filed with the FDA, as well as the generics which are licensed currently to Epic that will be coming back to Elite in late 2018, when that license expires.
our business is moving away from this type of revenue stream that is dependent on third parties.
2) the resources which were previously utilized for contract manufacturing were allocated to product development. Instead of making Methadone batches, these resources were used to run batches in products which are under development. In addition, we extended our lab and regulatory personnel to support this greatly increased product development activities.
The level of product development activity is the highest that I've seen since I've been here. And I've been with Elite since 2009.
3) there are three ANDAs already filed and under active review with the FDA. Also several other products in various stages of development that we expect will result in more ANDA filings over the near and mid-terms.
4) SequestOx - We are right now focusing on evaluating the right path forward for us to resolve this issue. Epic is negotiating and engaged with us. We've received several phone calls from them, offering their help and we made the announcement regarding the fat study.
5) Our ER products and pipeline are moving forward - And we are pursuing ER formulations. As a matter of fact, most of the money is in the ER extended release formulation
6) We started our aggressive program of filing one ANDA per quarter in Q3 of 2016. We filed one then and we filed another one in Q4, and a third in Q1 of 2017. We missed Q2 of 2017. We are scheduled to file one in Q3 of this year, so it's going to happen way before the end of this quarter and we are scheduled to file another one in Q4 by December.
7) The FDA has granted us 12-month extension for resubmission. One of my main concerns was if we missed this date by December of this year, which we will - that we will end our PDUFA fee and then we'll have to pay another one. We communicated with the FDA and they give us a 12-month extension. Now we can file any time in 2018 up to and through December 31, 2018 without asking for another extension if needed. And if the results are valid, we can proceed within that timeframe without paying another PDUFA fee.
8) we have many other valuable products that are progressing rapidly right now. At Elite, when we were manufacturing a little more, the number of [entries that I remember on our study] [ph] was about 13. And now, we're up to 50 and growing. And the reason we're growing even though the manufacturing part is not our primary focus and small, is because of all of these projects that are going to lead us within the next couple of years to becoming a seriously viable company. FYI, the total market size of the pipeline products that we are co-developing with SunGen is $6 billion.
9) All Elite needs is about $50 million in profit for our stock to go to dollar land, do the math. For our future growth, Elite pipeline will be the driver. We want to ensure a high rate of revenue growth by aggressively targeting one ANDA filing each quarter. Okay. As I stated earlier, out of the last four quarters we have submitted three ANDAs. We are scheduled to submit one this quarter and one in the quarter after.
10) we have completed the expansion of our manufacturing facility in preparation for our new product approval and launches.
ELTP highly undervalued from here!!!
$$$$ 20 Pathways to DollarLand $$$$
Working on 7 ADF opiods concurrently
1.) First ever generic ER 2 bead ADF labeled Oxycodone ELI-201
2.) First ever generic Embeda®
3.) First ever generic Troxyca® waiting on comparator product
4.) A $50 million dollar ANDA
5.) Approval/Launch of First ever one bead Abuse Deterrent generic (reformulated OxyContin® ) filed 09-20/2017
6.) File Huge Blockbuster Undisclosed NDA
7.) Lauch All four SunGen generics ($3 Billion combined markets)
8.) Buyout/Acquisition
9.)BP Partnership for entire ADF line
10.)Uplisting to NASDAQ
exchange 2018-19
11.) First ever ER opiod with out food restrictions
12.) Complete PH III trials for the first ever 24 hour
13.) Generic of Reformulated Opana ® ER
14.) First ADF opiod for Chinese Pain Market by PuraCap/Humanwell
15.) Canadian Approval of SequestOx ® - patents in place
16.) FDA accepts citizen petition urging the FDA to phase out oral prescription opioid analgesics that lack abuse-deterrent properties
17.) First ever Immediate Release ADF labeled opiod with ORAL AD Labeling on hold till FDA guidance received
18.) Launch an additional 4 SunGen generics
19.) Chinese approval of SequestOx ®
20.) European approval of AD oxycodone/opiod - patents in place
Gee more complete and utter BS.
5-24-13 "ELTP is going to be an easy 10 bagger from here"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=88285341&txt2find=10|bagger
Indeed - love how I called the 10 plus bagger and was picking up shares left and right. Next LOL LOL
LMAO; sure k
We shall see who loses this bet once Nasrat gets the warning letter removed. Next
Like I said - complete BS and my Fidelity account backs me up = WHOOPSY!!!
SXC continues buying SXCP at an aggressive pace - can you say BUYOUT $$$$$$
-major shareholder Sun Coal & Coke Llc bought 8,800 shares of the stock in a transaction dated Tuesday, October 17th. The shares were bought at an average cost of $17.77 per share, for a total transaction of $156,376.00.
-major shareholder Sun Coal & Coke Llc bought 7,900 shares of the stock in a transaction dated Wednesday, October 18th. The shares were bought at an average cost of $17.78 per share, for a total transaction of $140,462.00.